Advertisement

Accumulated experience in the physiology of glucagon

  • P. J. Lefèbvre
Chapter

Abstract

Before being a useful spasmolytic and hepatotrophic drug, glucagon is an important hormone exerting major metabolic effects in animals and in man. The explosion of our knowledge of glucagon is reflected by the size of some of the monographs and books devoted to glucagon and published over the last 30 years (Figure 1.1). The last comprehensive book on glucagon was published in 1983, and consists of two volumes totalling 1235 pages1. Most of the data summarized hereafter are developed in detail in the 56 chapters of these volumes.

Keywords

Plasma Glucagon Glucagon Release Adipose Tissue Lipolysis Gastric Inhibitory Peptide Spasmolytic Action 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lefèbvre PJ. Glucagon. Handb Exp Pharmacol 66 I and II. Berlin, Heidelberg, New York, Tokyo: Springer, 1983.Google Scholar
  2. 2.
    Bromer WW. Chemical characteristics of glucagon. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 1–22.Google Scholar
  3. 3.
    Merrifield RB, Mojsov S. The chemical synthesis of glucagon. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 23–25.Google Scholar
  4. 4.
    Orci L, Bordi C, Unger RH, Perrelet A. Glucagon- and glicentin-producing cells. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 661. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 57–79.Google Scholar
  5. 5.
    Lefèbvre PJ, Luyckx AS. Extrapancreatic glucagon and its regulation. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 205–219.Google Scholar
  6. 6.
    Hellerström C. Biosynthesis of glucagon. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 121–138.Google Scholar
  7. 7.
    Moody AJ, Thim L. Glucagon, glicentin and related peptides. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 139–174.Google Scholar
  8. 8.
    Bataille D, Gespach C, Tatemoto K, Marie JC, Caudray AM, Rosselin G, Mutt V. Bioactive enteroglucagon (oxyntomodulin): Present knowledge of its chemical structure and its biological activities. Peptides 1981; 2 (suppl 2): 41–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Korànyi L, Peterfy, F, Szabo J, Török A, Guoth M, Tamas GY Jr. Evidence for transformation of glucagon-like immunoreactivity of gut into pancreatic glucagon in vivo. Diabetes 1981; 30: 792–794.PubMedCrossRefGoogle Scholar
  10. 10.
    Bataille D, Tatemoto K, Gespach H, Jornvall H, Rosselin G, Mutt V. Isolation of glucagon- 37 (bioactive enteroglucagon/oxyntomodulin) from porcine jejuno-ileum. Characterization of the peptide. FEBS Lett 1982; 146: 79–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Depigny C, Lupo B, Kervran A, Bataille D. Mise en evidence d’un site récepteur spécifique du glucagon 37 (oxyntomoduline/entero-glucagon bioactif) dans les glandes oxyntiques du rat. CR Acad Sci (Paris) 1984; 299: 677–680.Google Scholar
  12. 12.
    Rodbell M. The actions of glucagon at its receptor: regulation of adenylate cyclase. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 263–290.Google Scholar
  13. 13.
    Stalmans W. Glucagon and liver glycogen metabolism. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 291–314.Google Scholar
  14. 14.
    Claus TH, Park CR, Pilkis SJ. Glucagon and gluconeogenesis. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 315–360.Google Scholar
  15. 15.
    McGarry JD, Foster DW. Glucagon and ketogenesis. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 383–389.Google Scholar
  16. 16.
    Lefèbvre PJ. Glucagon and adipose tissue lipolysis. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 419–440.Google Scholar
  17. 17.
    Korànyi L. Lipolytic effect of glucagon on perfused isolated human fat cells. Diabetologia 1983; 25: 172.Google Scholar
  18. 18.
    Lefèbvre PJ. Commentary: Glucagon and adipose tissue. Biochem Pharmacol 1975; 24: 1261–1266.PubMedCrossRefGoogle Scholar
  19. 19.
    Tiengo A, Nosadini R. Glucagon and lipoprotein metabolism. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 441–451.Google Scholar
  20. 20.
    Samols E, Marri G, Marks V. Promotion of insulin secretion by glucagon. Lancet 1965: 2: 415–416.PubMedCrossRefGoogle Scholar
  21. 21.
    Samols E. Glucagon and insulin secretion. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 485–518.Google Scholar
  22. 22.
    Leffert HL, Koch KS, Lad PJ, De Hemptinne B, Skelly H. Glucagon and liver regeneration. In: Lefèbvre PJ, ed. Glucagon I. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 453–484.Google Scholar
  23. 23.
    Kolanowski J. Influence of glucagon on water and electrolyte metabolism. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 525–536.Google Scholar
  24. 24.
    Lefèbvre PJ, Luyckx AS. Glucagon and catecholamines. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 537–543.Google Scholar
  25. 25.
    Farah AH. Glucagon and the heart. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 I. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 553–609.Google Scholar
  26. 26.
    Diamant D, Picazo J. Spasmolytic action and clinical use of glucagon. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 611–643.Google Scholar
  27. 27.
    Samols E, Weir GC, Bonner-Weir S. Intra-islet insulin-glucagon-somatostatin relationships. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 133–173.Google Scholar
  28. 28.
    Paolisso G, Sgambato S, Passariello N, Varrichio M. Scheen A, D’Onoŕrio F, Lefèbvre PJ. Pulsatile insulin delivery is more efficient than continuous infusion in modulating islet-cell function in normal subjects and in patients with type-I diabetes. (Submitted for publication.)Google Scholar
  29. 29.
    Gerich JE. Glucagon as a counter-regulatory hormone. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 275–295.Google Scholar
  30. 30.
    Lickley HLA, Kemmer FW, Wasserman DH, Vranic M. Glucagon and its relationship to other glucoregulatory hormones in exercise and stress in normal and diabetic subjects. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 297–350.Google Scholar
  31. 31.
    White NH, Skor DA, Cryer PE, Levandorsky LA, Bier DM. Identification of type-1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N. Engl J Med 1983; 308: 485–491.PubMedCrossRefGoogle Scholar
  32. 32.
    Gerich J, Davis J, Lorenzi M, Rizza R, Karam J, Lewis S, Kaplan R, Schultz T, Cryer P. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol 1979; 236: 380–385.Google Scholar
  33. 33.
    Luyckx AS, Pirnay F, Lefèbvre PJ. Effect of glucose on plasma glucagon and free fatty acids during prolonged exercise. Eur J Appl Physiol 1978; 39: 53–61.CrossRefGoogle Scholar
  34. 34.
    Lindsey CA, Faloona GR, Unger RH. Plasma glucagon levels during rapid exsanguination with and without adrenergic blockade. Diabetes 1975; 24: 313–319.PubMedCrossRefGoogle Scholar
  35. 35.
    Cahill GF Jr. Starvation in man. N Engl J Med 1970; 282: 668–675.PubMedCrossRefGoogle Scholar
  36. 36.
    Gelfand RA, Sherwin RS. Glucagon and starvation. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 223–237.Google Scholar
  37. 37.
    Girard J, Sperling M. Glucagon in the fetus and the newborn. In: Lefèbvre PJ, ed. Glucagon II. Handb Exp Pharmacol 66 II. Berlin, Heidelberg, New York, Tokyo: Springer, 1983: 251–274.Google Scholar
  38. 38.
    Foà PP. Galansino G. Glucagon. Chemistry and Function in Health and Disease. Springfield: CC Thomas, 1962.Google Scholar
  39. 39.
    Lefèbvre P. Le Glucagon, Seconde Hormone Pancréatique. Paris: Maloine, 1967.Google Scholar
  40. 40.
    Austoni M, Scandellari C, Federspil G, Trisotto A. Current Topics on Glucagon. Padova: CEDAM, 1971.Google Scholar
  41. 41.
    Lefèbvre PJ, Unger RH. Glucagon. Molecular Physiology, Clinical and Therapeutic Implications. Oxford: Pergamon Press, 1972.Google Scholar
  42. 42.
    Foà PP, Bajaj JS, Foà NL. Glucagon: Its Role in Physiology and Clinical Medicine. New York, Heidelberg, Berlin: Springer, 1977.Google Scholar

Copyright information

© MTP Press Limited 1987

Authors and Affiliations

  • P. J. Lefèbvre

There are no affiliations available

Personalised recommendations